Eligible patients had at least clinical and radiological evidence for refractory RAF/RASwt recurrent glioblastoma with molecular testing demonstrating no mutations in either BRAF, KRAS, or NRAS and stable or decreasing dosage of steroids for at least 7 days prior to the baseline magnetic resonance imaging (MRI)....Three patients discontinued treatment due to symptomatic deterioration (12%) and the other 2 patients were still on study treatment. Of the 24 evaluable patients, 21% had CB (n = 5) upon treatment with panitumumab. Two patients achieved a PR and 3 patients had SD at 16 weeks....The median PFS and OS were 1.7 months (95% CI 1.6-2.1 months) and 4.5 months (95% CI 2.9-8.6 months), respectively...